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Abstract Backgrouud: Care for patients with colon and rectal cancer has improved in the last 
twenty years however stili considerable variation exists in cancer management and outcome 
between European countries. Therefore, EURECCA, which is the acronym ofEuropean Reg-
istration of cancer care, is aiming at defining core treatment strategies and developing a Euro-
pean audit structure in order to improve the quality of care for all patients with colon and 
rectal cancer. In December 2012 the first multidisciplinary consensos conference about colon 
and rectum was held looking for moltidisciplinary consensos. The expert panel consisted of 
representatives of Eoropean scientific organisations in volved in cancer care of patients with 
colon and rectal cancer and representatives of national colorectal registries. 
Methods: The expert panel had delegates of the European Society of Surgical Oncology 
(ESSO), European Society for Radiotherapy & Oncology (ESTRO), European Society of 
Pathology (ESP), European Society for Medica! Oncology (ESMO), European Society of 
Radiology (ESR), European Society of Coloproctology (ESCP), European CanCer Organisa-
tion (ECCO), European Oncology Nursing Society (EONS) and the European Colorectal 
Cancer Patient Organisation (EoropaColon), as well as delega tes from national registries or 
aodits. Experts commented and voted on the two web-based online voting rounds before 
the meeting (between 4th and 25th October and between the 20th November and 3rd Decem-
ber 2012) as well as one online round after the meeting (4th-20th March 2013) and were 
invited to lecture on the subjects during the meeting (13th-15th December 2012). The sen-
terrees in the consensos document were available doring the meeting and a televoting round 
doring the conference by all participants was performed. All sentences that were voted on 
are available on the EURECCA website www.canceraudit.eu. 
The consensus document was divided in sections describing evidence based algorithms of diag-
nostics, pathology, sorgery, medical oncology, radiotherapy, and follow-up where applicable 
for treatment of colon cancer, rectal cancer and stage IV separately. Consensos was achieved 
using the Delphi method. 
Results: The total nomber of the voted sentences was 465. All chapters were voted on by at 
least 75% of the experts. Of the 465 sentences, 84% achieved large con~ensos, 6% achieved 
moderate consensus, and 7% resolted in minimum consensos, Only 3% was disagreed by more 
than 50% of the members. 
Conclusions: It ís feasible to achieve European Consensus on key diagnostic and treatment 
issoes osing the Delphi method. This consensus embodies the expertise of professionals from 
all disciplines involved in the care for patients with colon and rectal cancer. Diagnostic and 
treatment algorithms were developed to implement the current evidence and to define core 
treatment guidance for moltidisciplinary team management of colon and rectal cancer 
throughoot Europe. 
© 2013 Elsevier Ltd. Al! rights reserved. 
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l. Introduction 
Colon and rectal cancer (CRC) are the second most 
common cancers (1,234,000 cases worldwide in 2008 
according to GLOBO CAN and 342,137 in 27 country's 
in Europe in 2012) and cause many cancer related deaths 
each year (149,984 cases in Europe in 2012). 1•2 The fust 
two multidisciplinary consensus meetings on key issues 
in rectal cancer were held in 2004 and 2008 in Perugia, 
Italy. Because of the observed variation in incidence, 
treatment and outcome of colon andrecta! cancer world-
wide, the Third European Consensus meeting in Decem-
ber 2012 was organised for colon and rectal cancer. The 
meeting aimed lo outline the 'core quality treatment 
strategies' for colon and rectal cancer and reach cansen-
sus using the Delphi Method as applied in the previous 
editions. 3 In short>' we invited a multidisciplinary expert 
panel consisting of representa ti ves ofEuropean scientific 
organisations involved in providing cancer care to colon 
and rectal cancer patients, in arder to secure a :firm basis 
to reach the health professionals in the field. 
The mission of the European CanCer Organisation 
(ECCO) aims al 'Every patient deserves the bes! treat-
ment there is'. To optimise cancer care for patients with 
colon and rectal cancer, one of the key challenges is to 
strive for optimal multidisciplinary management of out-
come besides reaching a European consensus. High inci-
dence and potentially high curability of colon and rectal 
cancer accentuate that these patients deserve full atten-
tion and effort of a multidisciplinary team both befare 
neoadjuvant treatment or primary surgery as well as 
after surgery to decide on treatment strategies. 
The EUROCARE project, a European Union project 
to assemble survival data from population-based cancer 
registries, showed wide variation in rectal and colon 
cancer 5-year cumulative survival between different 
European countries in the nineties . .,_. Due to non-
acceptable results, severa! countries started quality 
registries and subsequently quality programmes were 
initiated based on these reports. The different features 
ofhealth care in Europe were explored and revealed that 
there is still a wide diversity of national guidelines and 
routine clinical practico and that every country has a dif-
ferent health care system, infrastructure and a different 
availability of registration of population based data."-' 
Since the beginning ofthe 1990s treatment of coloree-
tal cancer has changed substantial!y. At present, many 
countries have access to national and intemational 
guidelines? Adherence to guidelines is not always 
explored or monitored; improvements in securing pat-
terns of care are still ahead. Ideally, treatment decisions 
are nowadays made preoperatively and postoperatively 
in multidisciplinary boards. While Iater reports of 
EUROCARE showed that although survival was 
improving, inter-country variation is still r_rsisting, 
suggesting room for further improvement.5•1 Even in 
high-income countries with well established guidelines 
and a similar healthcare structure, the difference in out-
come is unexplained and vast. 11 Highly relevan! changos 
in the therapeutic approach have taken place in recen! 
years such as the implementation of the total mesorectal 
excision (TME)-technique for rectal cancer surgery.'4 
Another example of progress is preoperative treatment 
including radiotherapy and chemo radiotherapy for 
patients with rectal cancer and the incorporation of adju-
vant chemotherapy for patients with colon cancer."-17 
In the field of diagnostic imaging, primary staging has 
been improved, by introducing magnetic resonance 
imaging (MRI) in the preoperative work-up for rectal 
cancer18•19 and optimised computed tomography (CT) 
a!so contributed to more acócurate staging. Structured 
examination of surgical specimen, such as number of 
lymph nades and circumferential resection margin 
(CRM), Ieads to better postoperative identification of 
high risk patients?0 More and more countries are imple-
menting screening programmes for CRC, and guidelines 
for a high quality colorectal cancer screening in Europe 
have been published.21 A meta-analysis of randomised 
controlled trials reported that screening using flexible 
endoscopy reduces the incidence and mortality of colo-
rectal patients?2 Furthermore, treatment of patients 
with stage IV became more successful with broader 
acceptance of liver resection and improved chemother-
apy regimens. Overall, survival. has improved in most 
European countries over the past 20 years. In 1988-
1990 survival of patients with rectal cancer was Iower 
than that ofpatients with colon cancer. Survival ofrectal 
cancer nowadays surpasses the survival of colon cancer 
(in North Europe, United Kingdom [UK) and central 
Europe).23 Clinical audits were set up and severa! inter-
national trials were performed to improve loco regional 
control and survival of rectal cancer patients}4--29 
Based on the benefits achieved by national audits, 
European Society of Surgical Oncology (ESSO) has ini-
tiated the EURECCA-project in partnership with Euro-
pean Society for Radiotherapy & Oncology (ESTRO), 
European Society for Medica! Oncology (ESMO), Euro-
pean Society of Coloproctology (ESCP), ECCO, and 
European Organisation for Research and Treatment of 
Cancer (EORTC). EURECCA is the acronym ofEuro-
pean Registration of Cancer Care which aims to 
improve cancer outcome in Europe by comparing treat-
ment strategies and outcome of national audits.30 In 
arder to update the European consensus of multidisci-
plinary treatment guide!ines, the Third European Con-
sensos Conference Colon & Rectum was held in 
Perugia, Italy from 13th till 15th December 2012. 
2. Methodology 
Consensus was achieved by the Delphi Method using 
online web-based voting by experts and televoting 
Table 1 
Exarnples of sentences voted during the Consensus in Colon and Rectum Cancer Care.. 
Colon cancer Rectal cancer 
Diagnostic Radiology 
Obtain colonoscopy & biopsy preoperatively ifpossible. Completing colonoscopy to 
be performed soon after surgery if incomplete 
Lesser choice exams for location are sigmoidoscopy { only distal), Double Barium 
Contrast Enema. CT-abdomen 
CT --colonography could be considered only if necessary after an abdominal cr 
Abdominal and cbest CT for distant metastases is recommended 
Consider MRI liver for additional imaging of metastases if necessary 
There is no role for PET/CT sean in primary staging of colon cancer 
Bone or Brain imaging is recommended if symptoms are present 
Pathology 
Describe the used version of TNM and TNM stage in Pathology report 
Describe all margins, complete rbsection and perforation if applicable 
Describe lymph nade number and number of positive nades 
Descñbe other possible predictors ofpoor outcome; less than 10 LN, T4 tumours, 
lymphovascular invasion, extent of ttnnour spread beyond the musculairs 
propria, poor differentiation 
Surgery 
RO polypectomy ofTis or TI sml, witbout lympbovascular invasion and no poor 
differentiation invasion could be considered for follow up 
Fast track protocols when possible 
Anatomical resection followlllg the embryological planes is essential 
Training according to EAES guidelines, relative contraindications are obesity, 
previous open abdominal surgery and locally advanced disease 
Laparoscopic colectomy enhances postoperative recovery and has similar outcomes 
{survival) to open surgery in selected patients. Attention late/reactive converted 
patients do worse tban open 
Consider Stenting as a bridge to surgery, be aware ofris~s ofperforation, occlusion 
Chemotherapy 
No role for neoadjuvant chemotherapy in stage !-ID 
Chemotherapy in stage I is not recommended 
Adjuvant chemotherapy in stage II high risk could be considered 
Obtain colonoscopy & biopsy preoperatively if possible. Completing colonoscopy to be perfonned 
soon after surgery if incomplete 
. :rv.rn.I is mandatory in staging of all rectal cancers. Always describe cTNM and MRF, LN 
ntorphology in MRI report. Describe EMVI 
Abdontinal and chest cr for distant metastases is recommended 
Consider MR1 li.ver for additional imaging of metastases if necessary 
Tbere is no role for PET/CT sean in primary staging of colon cancer 
Bone or Brain imaging is recommended if symptoms are present 
Describe the used version of TNM and TNM stage in Pathology report 
Describe all m.argins, complete {mesorectum in Tl~3) resection and perforation if applicable 
Always describe CRM in mm from tumour free margin 
Describe iymph nade number and number of positive nades 
Describe other possible predictors of poor outcome; T4 tumours, lympbovascular invasion., extent of 
tumour spread beyond the musculairs propria, poor differentiation 
RO polYPectomy of Tis or TI sml, without lymphovascular invasion and no poor differentiation 
invasion could be considered for follow up 
If local excision is considered TEM is the procedure to perform 
Anatomical resection on careful preoperative planning based on IviRJ. TME surgery if possible is the 
gold standard 
Respect leaming curve and EAES guidelines for laparoscopic TME surgery 
Chemotherapy in stage I is not recommended 
Adjuvant chemotherapy in rectal cancer is to be considered in pathological stage ll/III 
(continued on nex~ page) 
.,. 
Table 1 
Examples of sentences voted during the Consensus in Colon and R.ectum Cancer Care. 
Colon cancer 
Adjuvant chemothernpy in stage ID and postoperative chemotherapy in stage IV is 
recommended 
Radiotherapy 
Only consider RT in selected T4 colon cancer patients with residual disease 
Follow up 
:ry!ore research needed 
CEA 
Rectal cancer 
Adjuvant chemoradiotherapy could be considered if no preoperative radiotherapy was given. 
Consider that preoperative radiotherapy is better 
Adjuvant chemotherapy can be considered after any preoperative treatment in stage IIITII 
No neoadjuvant treatmeut is recommended in early stages (cT1~2 NOMO) 
For high rectal tumours T3a/b no preoperative RT is recommended 
cT3 (MR.F~) NO MO consider three treatments; 
l. TME surgery and observation, 
2. 5x5 Gy and immediate TME surgery, 
3. chemoradiation followed by delayed TM:E surgery 
cT3 c/d (MRF~) or N+ MO recommend chemoradiotherapy befare TME surgery 
cT3 (MRF+) any N, MO or cT4, any N, MO preoperative downstaging with cbemoradiotherapy, 
followed by Tl\.ffi surgery or ex:tramesorectal excision ( exenteration) 
More research needed 
CEA 
Colonoscopy Colonoscopy 
In higb risk patients consider annual cr In high risk patients consider annual cr 
CT or PJIT/CT only in patients with positive :findings on routine follow up imaging cr or PET/CT only in patients with positive :findings on routine follow up imaging 
Consider at least 5 year FoDow up Consider at least 5 year Follow up 
Abbreviations: CT, computed tomography; :M:RI, magnetic resonance imaging; PET, positron emission tomography; 'INM, classification of malignant tumours; LN, lyrnph node; RO, no residual 
tumour; T4 Tumour. invasion ofother organs:; TIS Tumour, carcinoma in situ; sml, classification by Kudo; When less than one~third ofthe submucosa is invaded the stage is sml, and ifmore than two~ 
thirds is invaded the stage is sm3, while stage sm2 is intennediate with invasion of cancer into the middle third. Sml is when the depth of invasion is less ~1 mm or 1000 ¡.un from the muscularis 
mucosae. EAES, European Association for Endoscopic Surgery; ERAS, enhanced recovery after surgery; CEA, carcinoembryonic antigen; IviRF, meso rectal fascia; CRM, circumferentiai resection 
margin; RT, radiation therapy,,Gy, gray; RCT, chemoradiation; TME, total mesorectal excision. 
"' 
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during the meeting. The multidisciplinary expert panel 
consisted of representativos of European scientific 
organisations involved in cancer care of patients with 
colon and rectal cancer and representativos of national 
colorectal registries. The following organisations were 
involved; European Society of Surgical Oncology 
(ESSO), European Society for Radiotherapy & Oncol-
ogy (ESTRO), European Society of Pathology (ESP), 
European Society for Medica! Oncology (ESMO), Euro-
pean Society of Radiology (ESR), European Society of 
Coloproctology (ESCP), European CanCer Organisa-
tion (ECCO), European Oncology Nursing Society 
(EONS) and the European Colorectal Cancer Patient 
Organisation (EuropaColon). Experts commented and 
voted on the two online voting rounds befare the meet-
ing (4th-25th October 2012 and 20th November until 
the 3rd December 2012) as well as one online round 
after the meeting (4th-20th March 2013) and were 
invited to ]ecture on the subjects during the meeting 
(13th-15th December 2012) . .The sentences in the con-
sensus document were available during the meeting 
anda televoting round during the conference by all par-
ticipants was performed. Al! sentences that were voted 
on are available on the EURECCA website 
www.canceraudit.eu. 
The consensus document was divided in sections 
describing evidence based algorithms of diagnostics, 
pathology, surgery, medica! oncology, radiotherapy, 
and follow-up where applicable for treatment of colon 
cancer, rectal cancer and on stage N separately. 
3. Results. 
The Thhd Consensus Conference on Colon and Rectum, 
Pemgia, developed the follmving rnission statements; 
3.1. On audits and research 
patient deserves the best. We need to continually review 
what is the best treatment, identify over and under-treat-
ment, and determine the best care. We know that by 
working in a multidisciplinary environment together 
with specialist nurses and the patient, progress can be 
made. Examples of quality care treatment approaches 
discussed during the meeting are summarised in Table l. 
3.3. On quality of care 
Given the ímportance of each entity within the colo-
rectal cancer care process in determining outcome (sur-
gery, pathology, diagnostic imaging (in staging and 
restaging), radiotherapy and chemotherapy), quality 
assurance programmes including education and training 
programmes should become mandatary for colon and 
rectal cancer services to pro vide the best quality of care. 
There is a need for accessible and transparent structures 
for cancer care in Europe. 
Evidence based multidisciplinary management guide-
lines should be defined at national and European levels 
\vith the consensus of healthcare professionals, patient 
organisations and policy makers. 
4. Concluding remarks 
The Third Consensus Conference on colon and rec- . 
tum held in December 2012 achieved large consensus 
in 84% of the sentences proposed, meaning that more 
than 95% of the experts agreed on these sentences. 
Reaching consensus is deemed feasible and achievable 
in a large number ofkey items related to diagnosis, stag-
ing and treatment using the Delphi method. The chal-
lenge remains to assess whether this new consensus 
reaches the field and will be practiced by physicians 
across Europe, because stilllarge variations exist in clin-
ical practice across Europe. EURECCA is a platform to 
assess clínica! practice and quality, and to explore the 
relationship with survival. Also, different scientific soci-
eties and stakeholders could work together in arder to 
build a BU consensus in one of the most frequent can-
cers diagnosed in European countries. 
Contlict of interest statement 
National registries and audits are importan! to 
improve colorectal cancer survival. Definitions and 
guidelines should be comparable across Europe. Com-
bining large national datasets can identify 'best prac-
tices'. Both randomÍsed controlled trials and 
observational studies of large registries (national or 
European) are needed to identify key factors for the best 
colon and rectal cancer care. The strengths of large 
observational studies are related to providing outcome 
data on subgroups that are generally not included in 
clinical trials such as patients with co-morbidities and 
elderly. This will help professionals to optimise treat-
ment strategies for these specific subgroups. 
On behalf of the authors we state that the consensus 
meeting was possible due to a non-restrictive uncondi-
. tional Grant from ESSO. No other conflict of interest 
for this publication. 
3.2. On treatment 
Precision diagnosis will enable us to optimise staging 
and to individualise treatment. The rnission is that every 
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